Phathom Pharmaceuticals, Inc. Current Part of Debt

Current Part of Debt of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Part of Debt growth rates and interactive chart. Current debt or short-term debt are a firm's financial obligations that are expected to be paid off within a year. It also includes the portion of long-term debt that is due within a year. It is a part of the overall indebtedness of a company, and is included in Debt/Equity and Debt/Assets ratios.


Highlights and Quick Summary

  • Current Part of Debt for the quarter ending June 29, 2021 was $10.8 Million (a -11.57% decrease compared to previous quarter)
  • Year-over-year quarterly Current Part of Debt increased by 80.81%
  • Annual Current Part of Debt for 2020 was $7.83 Million (a 4761.49% increase from previous year)
  • Annual Current Part of Debt for 2019 was $161 Thousand (a -91.74% decrease from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Part of Debt of Phathom Pharmaceuticals, Inc.

Most recent Current Part of Debtof PHAT including historical data for past 10 years.

Interactive Chart of Current Part of Debt of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Current Part of Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $10.83 $12.24
2020 $7.83 $5.99 $1.81 $0.15 $7.83
2019 $0.16 $95.23 $0.16
2018 $1.95 $1.95

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.